Cellectis (CLSS) Confirms IPO Filing for Calyxt

Cellectis S.A. (Nasdaq : CLLS) and Calyxt, Inc. announced that Calyxt has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) of shares of Calyxt common stock. Calyxt is Cellectis’ 100% owned gene editing agriculture company. The number of shares to be offered and the price range for the offering have not yet been determined, although Cellectis intends to retain majority ownership of Calyxt.

Citigroup, Credit Suisse and Jefferies are acting as joint book-running managers for the proposed offering. Wells Fargo Securities is acting as lead manager and Ladenburg Thalmann is acting as co-manager.

You May Also Be Interested In

• B&R Technology Merger Corp. raises $325M in Nasdaq IPO
• China Pharma prices $5 million direct offering at $2 per share
• FDA grants priority review for Pfizer's Talzenna and Xtandi combo in prostate cancer